Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Nocardia rubra cell wall
skeleton plus hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and
leucovorin, lenvatinib and tislelizumab in patients with advanced hepatocellular carcinoma
(HCC).
Phase:
Phase 1
Details
Lead Sponsor:
Wan-Guang Zhang
Collaborators:
BeiGene Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province Chinese Cooperative Group of Liver Cancer (CCGLC) Geneis Geneplus-Beijing Co. Ltd. Haplox Biotechnology Co., Ltd. M&R Pharm Simcere Pharmaceutical Co., Ltd Yuce Biotechnology Co., Ltd.